Tersolisib
DrugTersolisib administered orally
Other names: LY4064809
NCT Number: NCT07662798
The main purpose of this study is to measure how food affects the amount of tersolisib that gets into the bloodstream. Each participant will receive two single oral doses of tersolisib, one under fasted conditions and one with either a high-fat or a low-fat meal. Blood tests will be performed to investigate how the body processes the study drug under each condition. For each participant, the study will last about 9 weeks and will include a stay in the Clinical Research Unit (CRU) lasting almost a month.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 1
Lenexa Clinic, Lenexa, Kansas, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tersolisib administered orally
Other names: LY4064809
High-fat Meal
Low-fat Meal
Time frame: Predose on Day 1 Through Day 28
Time frame: Predose on Day 1 Through Day 28
Contact information is provided by the study sponsor or research team.
Physicians interested in becoming principal investigators please contact
CONTACT
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Eli Lilly and Company
Industry
A Phase 1, Open-label Study to Assess the Effect of Food on the Pharmacokinetics of Tersolisib Administered Under Fasted Conditions, With a High-fat Meal, and With a Low-fat Meal, in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686393
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT07407348
Body Weight, Healthy
Nottingham, United Kingdom
View Trial DetailsNCT07169630
Alzheimer s Disease, Cognition Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT01399385
Arterial Occlusive Diseases, Arteriosclerosis
Bethesda, Maryland, United States
View Trial Details